Calithera Biosciences (NASDAQ:CALA) will be releasing its earnings data after the market closes on Thursday, August 8th. Analysts expect Calithera Biosciences to post earnings of ($0.55) per share for the quarter.
Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.18). On average, analysts expect Calithera Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
CALA opened at $4.20 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 6.75 and a quick ratio of 6.75. The firm’s 50-day moving average price is $4.29. Calithera Biosciences has a fifty-two week low of $3.43 and a fifty-two week high of $6.90. The company has a market capitalization of $165.99 million, a price-to-earnings ratio of -2.82 and a beta of 1.85.
A number of research firms recently weighed in on CALA. William Blair reissued a “buy” rating on shares of Calithera Biosciences in a research report on Friday, June 21st. ValuEngine raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Citigroup reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Calithera Biosciences in a research report on Thursday, May 30th.
In related news, insider Susan Molineaux acquired 51,600 shares of the stock in a transaction on Tuesday, June 25th. The shares were acquired at an average price of $3.88 per share, with a total value of $200,208.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 17.20% of the company’s stock.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.